BÜHLMANN Laboratories AG today announced the appointment of Christian Eberle as its new CEO.

Christian Eberle recently worked as CEO of Bacthera AG, a Basel based contract development and manufacturing organization in the live biotherapeutic product industry. Previously, he served as CEO of evitria AG, a global antibody expression service provider based in Zurich. Before becoming CEO, he had various leading manufacturing, strategic, and program management roles at Roche and Lonza. Christian earned a doctorate in medicinal and pharmaceutical chemistry at ETH Zurich and brings with him a wealth of scientific and business management experience that will enable us to achieve our growth ambitions. He will begin as BÜHLMANN Laboratories’ CEO on May 5, 2025.

Donal Quinn, chair of the BÜHLMANN Laboratories Advisory Board, said: “On behalf of the company and its shareholders, I am pleased to welcome Christian Eberle as BÜHLMANN Laboratories’ new CEO. I look forward to working with him and the executive management team on the key strategic initiatives to realize BÜHLMANN Laboratories’ full potential. I also like to thank Laurent Collignon for his valuable contribution as CEO to the development of the company since the acquisition by KLAR Partners”.